Adverse dermatoneurological events and impacts on daily activities of patients with gastrointestinal neoplasms undergoing chemotherapy.

Objective: to associate the presence and grading of adverse dermatoneurological events (peripheral neuropathy and hand-foot syndrome) and the interference in the activities of daily living of patients with gastrointestinal neoplasms undergoing systemic antineoplastic treatment.

Method: this is a longitudinal, prospective study, using instruments to assess hand-foot syndrome and peripheral neuropathy.

Results: there were 36 patients: 66.

Impact of interruptions on the duration of nursing interventions: A study in a chemotherapy unit.

Objective: To investigate interruptions during nursing interventions in a chemotherapy unit (sources and causes); measure their frequency, duration and the total elapsed time to complete the interventions.

Method: This is an observational analytical study performed using a digital stopwatch. It was conducted in a teaching hospital between 2015/2016.

Combined computational study of mechanical behaviour and drug delivery from a porous, hydroxyapatite-based bone graft.

This paper presents a numerical model of a porous, hydroxyapatite-based bone graft also suitable as a drug delivery device. The graft was positioned in different sites and with different porosities inside a human femur model. The structural analyses were carried out to verify the graft mechanical strength, using the Tsai-Wu criterion, and the maximum porosity at which static failure does not occur.

Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.

Background: Recombinant human TSH (rhTSH) is available for monitoring differentiated thyroid carcinoma. rhTSH testing modifies the guidelines for this disease.

Methods: A 2-year experience with rhTSH on 27 consecutive patients with papillary cancer is reported.

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.

Background: (131)I-metaiodobenzylguanidine ((131)I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur.